Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7041 in Active Noninfectious Uveitis
NCT07218770Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN7041 in noninfectious uveitis, sponsored by Regeneron Pharmaceuticals. Started Dec 2025; status: terminated.
02
Drugs
REGN7041
03
Conditions
noninfectious uveitis
Beyond the preview
Go deeper on NCT07218770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218770.